NASDAQ:ICLR - Icon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $145.19 +3.04 (+2.14 %) (As of 02/22/2019 04:00 PM ET)Previous Close$142.15Today's Range$142.18 - $145.6252-Week Range$110.21 - $155.33Volume217,500 shsAverage Volume272,108 shsMarket Capitalization$7.85 billionP/E Ratio23.08Dividend YieldN/ABeta0.71 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland. Receive ICLR News and Ratings via Email Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ICLR Previous Symbol CUSIPN/A CIK1060955 Webwww.iconplc.com Phone353-1291-2000Debt Debt-to-Equity Ratio0.26 Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E Ratio23.08 Forward P/E Ratio21.32 P/E Growth1.83 Sales & Book Value Annual Sales$2.60 billion Price / Sales3.02 Cash Flow$6.5667 per share Price / Cash Flow22.11 Book Value$22.02 per share Price / Book6.59Profitability EPS (Most Recent Fiscal Year)$6.29 Net Income$281.48 million Net Margins12.43% Return on Equity26.50% Return on Assets14.90%Miscellaneous Employees13,250 Outstanding Shares54,081,000Market Cap$7.85 billion Next Earnings Date5/1/2019 (Estimated) OptionableOptionable Icon (NASDAQ:ICLR) Frequently Asked Questions What is Icon's stock symbol? Icon trades on the NASDAQ under the ticker symbol "ICLR." How were Icon's earnings last quarter? Icon Plc (NASDAQ:ICLR) released its quarterly earnings results on Wednesday, February, 20th. The medical research company reported $1.62 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.60 by $0.02. The medical research company had revenue of $679.03 million for the quarter, compared to the consensus estimate of $675.04 million. Icon had a net margin of 12.43% and a return on equity of 26.50%. The company's quarterly revenue was up 49.2% on a year-over-year basis. During the same period last year, the firm earned $1.43 earnings per share. View Icon's Earnings History. When is Icon's next earnings date? Icon is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Icon. What guidance has Icon issued on next quarter's earnings? Icon updated its FY19 earnings guidance on Wednesday, February, 20th. The company provided earnings per share (EPS) guidance of $6.69-6.89 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.81. The company issued revenue guidance of $2.735 - $2.835 billion, compared to the consensus revenue estimate of $2.78 billion. What price target have analysts set for ICLR? 10 brokerages have issued 12-month target prices for Icon's stock. Their predictions range from $136.00 to $168.00. On average, they expect Icon's stock price to reach $150.5556 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for Icon. What is the consensus analysts' recommendation for Icon? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon. Has Icon been receiving favorable news coverage? Media coverage about ICLR stock has trended somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Icon earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of Icon's key competitors? Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL). What other stocks do shareholders of Icon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), Procter & Gamble (PG), Amgen (AMGN), Micron Technology (MU), Johnson & Johnson (JNJ), Visa (V), NVIDIA (NVDA), Mastercard (MA) and Alphabet (GOOG). Who are Icon's key executives? Icon's management team includes the folowing people: Dr. Steven A. Cutler, CEO & Director (Age 59)Mr. Brendan Brennan, Chief Financial Officer (Age 40)Jonathan Curtain, VP of Corp. Fin. & Investor RelationsMr. Thomas O'Leary, Chief Information OfficerMr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 44) Who are Icon's major shareholders? Icon's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (9.75%), Acadian Asset Management LLC (4.00%), Pendal Group Ltd (2.60%), Boston Partners (2.55%), Massachusetts Financial Services Co. MA (2.09%) and Principal Financial Group Inc. (1.95%). Which major investors are selling Icon stock? ICLR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Boston Partners, Mckinley Capital Management LLC Delaware, Chiron Investment Management LLC, Bank of America Corp DE, Lord Abbett & CO. LLC, Globeflex Capital L P and Principal Financial Group Inc.. Which major investors are buying Icon stock? ICLR stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, WCM Investment Management LLC, State of Tennessee Treasury Department, Blackcrane Capital LLC, Comgest Global Investors S.A.S., Massachusetts Financial Services Co. MA, Westfield Capital Management Co. LP and Northern Trust Corp. How do I buy shares of Icon? Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Icon's stock price today? One share of ICLR stock can currently be purchased for approximately $145.19. How big of a company is Icon? Icon has a market capitalization of $7.85 billion and generates $2.60 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,250 workers across the globe. What is Icon's official website? The official website for Icon is http://www.iconplc.com. How can I contact Icon? Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000. MarketBeat Community Rating for Icon (NASDAQ ICLR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 440 (Vote Outperform)Underperform Votes: 332 (Vote Underperform)Total Votes: 772MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What is a stock split?